Recent Posts

FDA approves Nexviazyme® (avalglucosidase alfa-ngpt)

In a recent announcement, the Pompe disease community learned that the U.S. Food and Drug Administration (FDA) has approved Nexviazyme® for the treatment of late-onset Pompe patients that are one year old and older.

What is Pompe disease?

Pompe disease is one of about 50 Lysosomal Storage Disorders. Pompe patients are deficient in the critical enzyme acid alpha-glucosidase.


About CAP

We are committed to helping Pompe patients and their families in Canada through education, support and community.



Ways to connect with other patients & families and social media opportunities to stay informed.


New Patients and Families

Welcome to the wonderful world of rare disease. It’s a much different world than it was a few years ago. There’s so much information out there, and there are places to turn for support and friendship. With social media, especially Facebook and Twitter, there are answers.

There are patient advocacy groups all over the world, of which CAP is one of them.

New Brunswick, 2014

Out of a stormy cloud comes a whole bunch o’ crazy people waving their hands… at the 2014 Fredericton Walk for Muscular Dystrophy. We were fortunate to gather in New Brunswick for our 2014 CAP Conference and were humbled to be presented with the Kaitlyn Hatchard Award with Annette Sebey.

Connect with us


Mailing Address

112-3201 Wilson St
Penticton, BC,
V2A 8J3

Follow us on Twitter

#Pompe Empowerment Program 2022 starts in less than an hour! Still time to register! #RareDisease #PompeDisease
Join us for our Pompe Empowerment Program 2022! Register for this Zoom event, that starts Sunday, Jan 16 at 7pm ET. We have some great expert and patient speakers. #PompeDisease #RareDisease #Pompe